Prescription Required
Formulation: Film Coated Tablet
(Brand Option)
Select the prescribed dosage
Select the quantity to see the price.
Prescription Required
Formulation: Film Coated Tablet
(Generic Alternative)
Select the prescribed dosage
Select the quantity to see the price.
* This price includes a dispensing fee, medical review fee, and packing fee.
Shipped and delivered directly to your doorstep
Savaysa contains the active ingredient edoxaban tosilate. It is a prescription anticoagulant, sometimes called a blood thinner, used to reduce the risk of harmful blood clots.
Savaysa is used to reduce the risk of stroke and systemic embolism in certain adults with nonvalvular atrial fibrillation.
Atrial fibrillation is an irregular heart rhythm that can allow blood to pool inside the heart. This can lead to the formation of blood clots.
If a clot travels from the heart to the brain, it can cause a stroke. If it travels to another part of the body, it can cause a systemic embolism.
Savaysa helps reduce this risk by making it harder for harmful blood clots to form.
Savaysa is also used to treat deep vein thrombosis (DVT).
A DVT is a blood clot that forms in a deep vein, most commonly in the leg. Symptoms may include:
A DVT can become dangerous if part of the clot breaks away and travels to the lungs.
Savaysa may also be used to treat pulmonary embolism (PE).
A pulmonary embolism occurs when a blood clot travels to the lungs and blocks blood flow.
Symptoms can include sudden shortness of breath, chest pain, rapid heartbeat, coughing, or coughing up blood. A pulmonary embolism can be life-threatening and requires prompt medical treatment.
For DVT or PE, Savaysa is generally started after 5 to 10 days of treatment with an injectable anticoagulant, such as heparin.
After this initial treatment, Savaysa helps treat the existing blood clot and reduce the risk of another DVT or PE developing.
Savaysa belongs to a group of medications called direct oral anticoagulants (DOACs).
More specifically, edoxaban is a factor Xa inhibitor.
Factor Xa is an important protein involved in the body’s blood-clotting process. By blocking factor Xa, Savaysa reduces the production of thrombin, which is needed to form stable blood clots.
This decreases the blood’s ability to form harmful clots.
Savaysa does not directly break apart an existing blood clot.
Instead, it helps prevent the clot from getting larger and reduces the formation of new clots. This gives the body’s natural processes time to gradually break down the existing clot.
When taken as prescribed, Savaysa can help reduce the risk of serious complications caused by blood clots, including:
Because Savaysa reduces blood clotting, it can also increase the risk of bleeding. The dose and duration of treatment should therefore be carefully determined by a healthcare provider.
Kidney function is an important consideration when Savaysa is prescribed.
For nonvalvular atrial fibrillation, Savaysa is not recommended in patients with a creatinine clearance greater than 95 mL/min because it may be less effective at preventing stroke in these patients.
Kidney function is also used to determine whether a lower dose is needed. Your healthcare provider may check your kidney function before and during treatment.
The length of Savaysa treatment depends on why you are taking it, your risk of developing another blood clot, your bleeding risk, kidney function, and your overall medical condition.
Do not stop Savaysa without speaking with your healthcare provider. Stopping anticoagulant treatment too soon may increase the risk of stroke or another blood clot.
Savaysa is taken by mouth once daily, with or without food.
Take it at about the same time each day to help you remember your dose and maintain consistent anticoagulant protection.
The dose depends on why you are taking Savaysa, your kidney function, body weight, and certain other medications you use.
For adults with nonvalvular atrial fibrillation, the recommended dose is 60 mg once daily when creatinine clearance is greater than 50 mL/min but no higher than 95 mL/min.
The dose is reduced to 30 mg once daily when creatinine clearance is 15 to 50 mL/min.
Savaysa should not be used for nonvalvular atrial fibrillation when creatinine clearance is greater than 95 mL/min, because it may be less effective at preventing ischemic stroke in these patients.
For the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), Savaysa is started after 5 to 10 days of treatment with an injectable anticoagulant.
The usual dose is 60 mg once daily.
The dose is reduced to 30 mg once daily if you:
Your healthcare provider will determine the appropriate dose for you.
Swallow Savaysa as directed by your healthcare provider.
If you have difficulty swallowing the tablet whole, follow the administration instructions provided with your medication or ask your pharmacist about an appropriate alternative way to take it.
Take the full prescribed dose and do not change the tablet strength or dosing schedule on your own.
Take Savaysa every day as prescribed.
Missing doses can reduce your protection against stroke or blood clots. Do not stop taking Savaysa without speaking with your healthcare provider unless you are having a medical emergency involving serious bleeding.
Stopping an anticoagulant too early without another appropriate anticoagulant may increase the risk of stroke or other blood-clotting events.
If you miss a dose of Savaysa, take it as soon as you remember on the same day.
Then take your next dose at the usual time the following day.
Do not take two doses at the same time or take extra Savaysa to make up for the missed dose.
Your healthcare provider will assess your kidney function before starting Savaysa because kidney function affects the dose and whether the medication is appropriate.
Kidney function may also be checked during treatment, especially if your health changes or you develop a condition that could affect your kidneys.
Tell your healthcare provider about all prescription medications, over-the-counter products, vitamins, supplements, and herbal products you use.
Some medications can change how Savaysa works or increase your risk of bleeding. Do not start or stop another medication without checking with your healthcare provider or pharmacist.
Savaysa (Edoxaban Tosilate) is available in the following forms and strength:
Bleeding Risk
Savaysa increases the risk of bleeding because it reduces the blood’s ability to clot.
Bleeding can sometimes be serious or life-threatening. Tell your healthcare provider if you have a history of bleeding problems or if you take other medications that can increase bleeding risk.
These may include:
Seek medical attention if you develop unusual or severe bleeding, black or bloody stools, vomiting or coughing up blood, severe headache, unexplained weakness, or bleeding that does not stop.
Do not stop Savaysa without speaking with your healthcare provider unless you are experiencing a medical emergency involving serious bleeding.
Stopping Savaysa too early without another appropriate anticoagulant can increase the risk of stroke or other blood-clotting events.
If Savaysa needs to be discontinued, your healthcare provider may recommend another anticoagulant to maintain protection against blood clots.
Kidney function affects how Savaysa is removed from the body.
About half of edoxaban clearance occurs through the kidneys, so reduced kidney function can increase Savaysa levels and raise the risk of bleeding.
For patients with a creatinine clearance of 15 to 50 mL/min, a lower dose may be required. Savaysa is generally not recommended when creatinine clearance is below 15 mL/min.
For patients taking Savaysa for nonvalvular atrial fibrillation, kidney function that is too high can also be important.
Savaysa is not recommended when creatinine clearance is greater than 95 mL/min because it may be less effective at preventing ischemic stroke in these patients.
Tell your healthcare provider if you have liver disease.
Savaysa is not recommended in patients with moderate or severe liver impairment, because these patients may already have abnormalities in blood clotting.
No dose reduction is generally required for mild liver impairment.
Tell your surgeon, dentist, or other healthcare provider that you take Savaysa before having surgery or an invasive procedure.
Because Savaysa increases bleeding risk, it may need to be temporarily stopped before certain procedures.
Do not stop it on your own. Your healthcare provider will tell you when to stop and when to restart treatment.
Patients taking Savaysa who receive spinal or epidural anesthesia or undergo a spinal puncture may be at risk of developing a spinal or epidural hematoma.
This collection of blood around the spinal cord can cause long-term or permanent paralysis.
Seek immediate medical attention if you develop back pain, numbness, tingling, muscle weakness, or loss of bladder or bowel control after a spinal procedure.
Savaysa can interact with other medications.
Some drugs can increase bleeding risk, while others may reduce the effectiveness of Savaysa.
Tell your healthcare provider about all prescription medications, over-the-counter products, vitamins, supplements, and herbal products you use.
Do not start or stop another medication without checking with your healthcare provider or pharmacist.
Heavy alcohol use can increase the risk of bleeding and may also increase the chance of falls or injuries while taking an anticoagulant.
It is best to discuss alcohol use with your healthcare provider, especially if you drink regularly or have liver problems.
Older adults can use Savaysa, and clinical studies found generally similar effectiveness and safety compared with younger adults.
However, bleeding risk can still increase with age because of changes in kidney function, other medical conditions, or the use of multiple medications.
Your healthcare provider may monitor kidney function and bleeding risk more closely.
Tell your healthcare provider if you are pregnant, think you may be pregnant, or plan to become pregnant.
Anticoagulants can increase the risk of bleeding during pregnancy. Your healthcare provider will determine whether Savaysa is appropriate based on your need for anticoagulation and your individual risks.
Do not stop Savaysa on your own if you become pregnant.
Breastfeeding is not recommended during Savaysa treatment.
It is not known whether edoxaban passes into human breast milk, but because serious bleeding could potentially occur in a nursing infant, current prescribing information advises against breastfeeding while taking Savaysa.
Seek urgent medical attention if you develop signs of a serious allergic reaction, such as:
Savaysa does not usually require routine INR testing like warfarin.
However, your healthcare provider may periodically monitor:
Regular follow-up helps make sure the dose remains safe and appropriate.
Tell your healthcare provider if you are pregnant, think you may be pregnant, or plan to become pregnant. Savaysa can increase the risk of bleeding, so your healthcare provider will weigh the potential benefits of treatment against the possible risks during pregnancy. Breastfeeding is generally not recommended while taking Savaysa because it is not known whether edoxaban passes into human breast milk and there may be a risk of serious bleeding in a nursing infant. Do not stop Savaysa on your own if you become pregnant.
The length of Savaysa treatment depends on why you are taking it, your risk of developing another blood clot or stroke, your bleeding risk, kidney function, and overall medical history. Some people may need Savaysa for several months, while others may require longer-term treatment. Your healthcare provider will determine how long treatment should continue. Do not stop Savaysa without speaking with your healthcare provider.
If you miss a dose of Savaysa, take it as soon as you remember on the same day. Then take your next dose at the usual scheduled time the following day. Do not take two doses at the same time or take extra Savaysa to make up for a missed dose.
Savaysa begins working relatively quickly after a dose is taken. Edoxaban reaches peak blood levels within about 1 to 2 hours, so its anticoagulant effect begins within the first few hours after taking a dose. Savaysa does not actually “thin” the blood. Instead, it blocks factor Xa, an important part of the clotting process, which reduces the blood’s ability to form harmful clots.
| Generic name: | Edoxaban Tosilate, Edoxaban Tosylate monohydrate |
|---|---|
| Formulation: | Film Coated Tablet, Tablet |
| Strength(s): | 30mg, 60mg |
| Quantities Available: | 84, 100 |
Our online Canadian Pharmacy is known for high standards of quality, safety, and efficiency when it comes to medications.
Our pharmacy offers lower prices on prescription drugs compared to traditional pharmacies.
When ordering Savaysa (edoxaban tosilate) from a Canadian pharmacy, you can typically purchase up to a 90-day supply at one time, which is common for prescription medications to ensure adequate management of chronic conditions without frequent refills.
Here’s what you need to know:
Dosage and Quantity: Savaysa is commonly prescribed in dosages of 30 mg or 60 mg, taken once daily. For a 90-day supply, this means you would order 90 tablets (90 days x 1 tablet per day).
No, we do not sell edoxaban tosilate on our website. However, you can still enjoy low prices on Savaysa, which contains edoxaban tosilate as an active ingredient. To purchase Savaysa, you will need a valid prescription from your healthcare provider. We require this prescription to dispense the medication. You can conveniently submit your prescription by mail, fax, or upload it through your online account.
Yes, we ship Savaysa (edoxaban tosilate) to both the United States and Puerto Rico.
Watch how Online Pharmacies Canada is helping customers save money on their medications.
Online Pharmacies Canada has provided information from third parties intended to increase awareness and does not contain all the information about Savaysa (Edoxaban Tosilate). Talk to your doctor or other qualified medical practitioners for medical attention or advice, or if you have any concerns about Savaysa (Edoxaban Tosilate).
REVIEWS